MedPath
Found 7 clinical trials|View Analysis
Sort by:

Patient and Caregiver Priorities in Neuro-oncology Care

Recruiting
Conditions
Malignant Central Nervous System Neoplasm
Metastatic Malignant Neoplasm in the Central Nervous System
First Posted Date
2024-11-06
Last Posted Date
2024-11-06
Lead Sponsor
Mayo Clinic
Target Recruit Count
80
Registration Number
NCT06676306
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

Phase 1
Recruiting
Conditions
Metastatic Malignant Neoplasm in the Central Nervous System
Metastatic Melanoma
Metastatic Malignant Neoplasm in the Brain
Clinical Stage IV Cutaneous Melanoma AJCC v8
Interventions
Drug: Dabrafenib
Drug: MEK-1/MEKK-1 Inhibitor E6201
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
First Posted Date
2022-05-24
Last Posted Date
2024-03-29
Lead Sponsor
Mayo Clinic
Target Recruit Count
18
Registration Number
NCT05388877
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Phase 1
Recruiting
Conditions
Diffuse Midline Glioma, H3 K27M-Mutant
Recurrent Diffuse Intrinsic Pontine Glioma
Metastatic Malignant Neoplasm in the Central Nervous System
Recurrent Osteosarcoma
Refractory Malignant Solid Neoplasm
Refractory Primary Malignant Central Nervous System Neoplasm
Recurrent Lymphoma
Recurrent Primary Malignant Central Nervous System Neoplasm
Refractory Osteosarcoma
Refractory Lymphoma
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspirate
Procedure: Bone Marrow Biopsy
Procedure: Echocardiography
Drug: FACT Complex-targeting Curaxin CBL0137
First Posted Date
2021-05-04
Last Posted Date
2024-12-04
Lead Sponsor
Children's Oncology Group
Target Recruit Count
95
Registration Number
NCT04870944
Locations
🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

Children's Hospital of Orange County, Orange, California, United States

and more 29 locations

An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors

Not Applicable
Completed
Conditions
Central Nervous System Neoplasm
Metastatic Malignant Solid Neoplasm
Glioma
Metastatic Malignant Neoplasm in the Central Nervous System
Interventions
Procedure: 7 Tesla Magnetic Resonance Imaging
Other: Questionnaire Administration
First Posted Date
2020-09-07
Last Posted Date
2025-01-08
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
50
Registration Number
NCT04539574
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer with Central Nervous System Metastases

Phase 1
Recruiting
Conditions
Anaplastic Astrocytoma, IDH-Wildtype
Glioblastoma, IDH-Wildtype
Metastatic Lung Non-Small Cell Carcinoma
Metastatic Malignant Neoplasm in the Central Nervous System
Interventions
Procedure: Biospecimen Collection - blood samples
Procedure: Biospecimen Collection - CSF samples
Procedure: Computed Tomography
Drug: EGFR/EGFRvIII Inhibitor WSD0922-FU
Procedure: Therapeutic Conventional Surgery
Procedure: Magnetic Resonance Imaging
First Posted Date
2019-12-13
Last Posted Date
2024-11-26
Lead Sponsor
Mayo Clinic
Target Recruit Count
55
Registration Number
NCT04197934
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

Phase 2
Withdrawn
Conditions
ALK Gene Amplification
Advanced Malignant Neoplasm
ALK Gene Mutation
ROS1 Fusion Positive
ALK Fusion Protein Expression
Metastatic Malignant Neoplasm in the Brain
Locally Advanced Malignant Solid Neoplasm
Metastatic Malignant Neoplasm in the Central Nervous System
Metastatic Malignant Solid Neoplasm
ROS1 Gene Amplification
Interventions
Drug: Brigatinib
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
First Posted Date
2019-03-11
Last Posted Date
2022-02-18
Lead Sponsor
Sameek Roychowdhury
Registration Number
NCT03868423
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors

Phase 1
Completed
Conditions
Metastatic Malignant Neoplasm in the Central Nervous System
Malignant Central Nervous System Neoplasm
Interventions
Other: Gadolinium
Drug: Hyperpolarized Carbon C 13 Pyruvate
Procedure: Magnetic Resonance Imaging
Procedure: Magnetic Resonance Spectroscopic Imaging
First Posted Date
2018-06-21
Last Posted Date
2023-12-21
Lead Sponsor
Daniel M. Spielman
Target Recruit Count
9
Registration Number
NCT03565367
Locations
🇺🇸

Stanford University School of Medicine, Palo Alto, California, United States

© Copyright 2025. All Rights Reserved by MedPath